Nia Impact Advisors LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 21.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 54,400 shares of the biopharmaceutical company's stock after selling 15,059 shares during the quarter. Gilead Sciences accounts for 1.6% of Nia Impact Advisors LLC's investment portfolio, making the stock its 21st biggest holding. Nia Impact Advisors LLC's holdings in Gilead Sciences were worth $5,025,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of the stock. Nicolet Advisory Services LLC increased its stake in shares of Gilead Sciences by 2.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock worth $322,000 after acquiring an additional 100 shares during the last quarter. Southland Equity Partners LLC boosted its holdings in Gilead Sciences by 3.6% during the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock valued at $289,000 after acquiring an additional 110 shares during the period. Berkshire Bank boosted its holdings in Gilead Sciences by 3.4% during the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock valued at $314,000 after acquiring an additional 111 shares during the period. CFO4Life Group LLC raised its position in shares of Gilead Sciences by 2.7% during the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock valued at $394,000 after buying an additional 112 shares during the last quarter. Finally, Howe & Rusling Inc. raised its position in shares of Gilead Sciences by 2.5% during the fourth quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company's stock valued at $435,000 after buying an additional 115 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences Price Performance
Shares of NASDAQ:GILD traded up $2.16 during trading on Friday, reaching $102.50. The stock had a trading volume of 6,395,303 shares, compared to its average volume of 7,677,426. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The business's 50-day moving average price is $105.75 and its 200 day moving average price is $99.76. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market capitalization of $127.50 billion, a PE ratio of 277.03, a P/E/G ratio of 0.71 and a beta of 0.26.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter in the previous year, the company posted ($1.32) earnings per share. Gilead Sciences's quarterly revenue was down .3% compared to the same quarter last year. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.08%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on GILD. Wells Fargo & Company upped their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. BMO Capital Markets upped their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price objective for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Finally, Piper Sandler upped their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $110.55.
Get Our Latest Stock Report on GILD
Insider Activity at Gilead Sciences
In related news, CFO Andrew D. Dickinson sold 17,929 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now owns 169,061 shares of the company's stock, valued at $19,977,938.37. This trade represents a 9.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 25,429 shares of company stock valued at $2,894,445 over the last quarter. Corporate insiders own 0.27% of the company's stock.
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
